Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA
- 09.01.2019
- Original Article
Erschienen in:
- Verfasst von
- Lisa M. Hess
- Zhanglin Lin Cui
- Daniel S. Mytelka
- Yimei Han
- Robert Goodloe
- William Schelman
- Erschienen in
- International Journal of Colorectal Disease | Ausgabe 4/2019
Abstract
Background
Colorectal cancer is the third most common cause of cancer death in the USA. It is important to identify patients who may experience poor outcomes from available treatments.
Methods
In this retrospective observational study, treatment patterns and survival outcomes were described among adult patients from the Flatiron Health electronic medical records database who were treated with at least two lines of therapy for metastatic colorectal cancer in the USA between January 2013 and May 2018. Patients with rapid progression were defined as those whose time from start of first- to second-line therapy was ≤ 183 days.
Results
A total of 14,315 patients formed the study cohort. The most common first-line treatments were FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) plus bevacizumab, received by 34.7% (n = 4962) of patients, followed by FOLFOX alone (17.1%, n = 2445). Of all patients, 6991 (48.9%) also received second-line anti-cancer therapy and of those, 3338 (47.7%) had rapid progression and 3653 (52.3%) did not. Median overall survival from the start of first- and second-line therapy was 20.8 months (95% CI 20.2–21.3) and 14.5 months (95% CI 13.9–15.0) for the entire study population, respectively. Median overall survival from the start of second-line therapy was 14.1 (95% CI 13.2–14.8) for patients with rapid progression and 14.6 months (95% CI 13.8–15.4) for patients without rapid progression.
Conclusions
Patients diagnosed with metastatic colorectal cancer lived less than 2 years in this real-world database. While the time to initiation of second-line therapy was by definition longer among patients without rapidly progressing disease, survival outcomes were comparable from initiation of second-line therapy.
Anzeige
- Titel
- Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA
- Verfasst von
-
Lisa M. Hess
Zhanglin Lin Cui
Daniel S. Mytelka
Yimei Han
Robert Goodloe
William Schelman
- Publikationsdatum
- 09.01.2019
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
International Journal of Colorectal Disease / Ausgabe 4/2019
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262 - DOI
- https://doi.org/10.1007/s00384-018-03227-5
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
